Literature DB >> 7514152

Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer.

F el Atiq1, F Garrouste, M Remacle-Bonnet, B Sastre, G Pommier.   

Abstract

It has been reported that insulin-like growth factor (IGF) II is associated with human primary colorectal tumors and colon-carcinoma cell lines. Here, we examine alterations in circulating levels of IGFs and IGF binding proteins (IGFBPs) in patients with colorectal carcinoma, and compare them to age- and nutrition-adjusted references. We report (i) an increase in serum IGF-II concentrations (about 2-fold), whereas IGF-I concentrations are regarded as normal when aging is taken into account; (ii) an apparent increase in serum IGFBP-3 levels when compared to those of healthy elderly subjects, IGFBP-3 only being detected in the 150-kDa IGFBP ternary complex as in normal serum; (iii) abnormally elevated serum IGFBP-2 levels taking into account the apparent concentrations of IGFBP-3. This simultaneous elevation of IGFBP-3 and IGFBP-2 in the serum of patients with colorectal tumors appears to be unique in that it reflects a break in the inverse relationship between the serum IGFBP-3 and IGFBP-2 levels that is observed in normal and in several physiopathological conditions. Moreover, it enables a distinction to be made between 76.5% (13/17) of patients with colorectal carcinoma and normal adults, age-related healthy aged and malnourished patients. We propose that the disturbed serum IGFBP profile observed in the patients with colorectal cancer may be a consequence of oversecretion of IGF-II by the tumor cells. The usefulness of IGFs and IGFBPs as potential colorectal tumor-associated metabolic markers should be further investigated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514152     DOI: 10.1002/ijc.2910570409

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

Review 1.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

Review 2.  The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge.

Authors:  Rajaraman Durai; Wenxuan Yang; Sharmila Gupta; Alexander M Seifalian; Marc C Winslet
Journal:  Int J Colorectal Dis       Date:  2005-01-14       Impact factor: 2.571

3.  MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma.

Authors:  Swadesh K Das; Sujit K Bhutia; Belal Azab; Timothy P Kegelman; Leyla Peachy; Prasanna K Santhekadur; Santanu Dasgupta; Rupesh Dash; Paul Dent; Steven Grant; Luni Emdad; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Res       Date:  2012-12-10       Impact factor: 12.701

4.  Serum levels of insulin-like growth factors (IGF-I and IGF-II) and their binding protein (IGFBP-3) are not elevated in pancreatic cancer.

Authors:  J D Evans; M C Eggo; I A Donovan; S R Bramhall; J P Neoptolemos
Journal:  Int J Pancreatol       Date:  1997-10

5.  Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20.

Authors:  Gianluca Marucci; Luca Morandi; Elisabetta Magrini; Anna Farnedi; Enrico Franceschi; Rossella Miglio; Daniela Calò; Annalisa Pession; Maria P Foschini; Vincenzo Eusebi
Journal:  Virchows Arch       Date:  2008-10-25       Impact factor: 4.064

6.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

Review 7.  Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician.

Authors:  Kevin C J Yuen; Anthony P Heaney; Vera Popovic
Journal:  Endocrine       Date:  2016-01-05       Impact factor: 3.633

8.  PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions.

Authors:  Kenichi Miyako; Laura J Cobb; Malik Francis; Alden Huang; Bonnie Peng; John E Pintar; Hiroyoshi Ariga; Pinchas Cohen
Journal:  Mol Endocrinol       Date:  2008-12-18

9.  Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer.

Authors:  Takuya Yazawa; Hanako Sato; Hiroaki Shimoyamada; Koji Okudela; Tetsukan Woo; Michihiko Tajiri; Takashi Ogura; Nobuo Ogawa; Takehisa Suzuki; Hideaki Mitsui; Jun Ishii; Chie Miyata; Masashi Sakaeda; Kazuya Goto; Korehito Kashiwagi; Munetaka Masuda; Takashi Takahashi; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2009-08-13       Impact factor: 4.307

10.  The insulin-like growth factor system and its receptors: A potential novel anticancer target.

Authors:  Colin R Lindsay; Tr Jeffry Evans
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.